{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-22-026611","form_type":"8-K","ticker":"ZVRA","cik":"0001434647","company_name":"ZEVRA THERAPEUTICS, INC.","filed_at":"2022-11-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.643577+00:00","generated_at":"2026-06-22T01:03:48.126421+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"KemPharm Q3 net loss widens to $0.19/shr; cash $107.4M, runway into 2026","bullets":["Net loss of $6.6M ($0.19/share) vs loss of $1.8M ($0.05) in Q3 2021; revenue $2.9M (+45% YoY).","R&D expense $5.4M (up from $2.2M) on KP1077 and arimoclomol programs; G&A $4.0M (up from $1.9M).","Cash and investments $107.4M as of Sep 30, 2022; based on current forecast, runway extends into 2026.","Arimoclomol NDA resubmission for NPC expected as early as Q3 2023; ongoing FDA discussions.","KP1077 Phase 2 trial in IH to initiate by year-end 2022; Phase 1 CV safety trial completed."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-22-026611","json":"https://secwatch.observer/filing/0001437749-22-026611.json","markdown":"https://secwatch.observer/filing/0001437749-22-026611.md","text":"https://secwatch.observer/filing/0001437749-22-026611.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1434647/000143774922026611/0001437749-22-026611-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1434647/000143774922026611/kmph20220904_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T01:03:48.126421+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"0f0a338804b49185a5ab1604f46945355ffbb43b","claim":"ZEVRA THERAPEUTICS, INC. reported the third quarter ended September 30, 2022 results: revenue $2.9 million, net income ($6.6) million, or ($0.19) per basic and diluted share.","evidence_excerpt":"strategy could provide further capital flexibility and extend the operating cash runway. Overview of Third Quarter 2022 Financial Results: Net revenue for Q3 2022 was $2.9 million, as compared to Q3 2021 net revenue of $2.0 million. The period-over-period increase was primarily attributed to revenue from the arimoclomol Early Access Program (EAP) in","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1434647/000143774922026611/0001437749-22-026611-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Revenue","value":"$2.9 million"},{"label":"Net income","value":"($6.6) million, or ($0.19) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}